STAMFORD, Conn., Dec. 16 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (NASDAQ:DCTH) announced today it has extended the redemption date for its outstanding 2005 Redeemable Common Stock Purchase Warrants - Series A (NASDAQ: DCTHZ). The extended redemption date is December 23, 2005, at which time all necessary steps to exercise the warrants must be properly completed by 5:00 P.M., Eastern Time. Delcath made the Notice of redemption on November 15, which was sent to all brokerage firms holding the Warrants for their clients. The Company has since received several calls from warrant holders, informing management that some brokerage firms failed to notify them of the redemption offer in a timely fashion prior to the deadlines. In light of this fact, Delcath has decided to extend the redemption offer to allow these holders the opportunity to sell or exercise those remaining Warrants. Because the Warrants are subject to a redemption offer, any holders who elect not to exercise their warrants by the expiration date will be entitled to receive $0.10 for each remaining Warrant upon surrender of the Warrant to the transfer agent. About Delcath Systems, Inc. Delcath Systems is a developer of isolated perfusion technology for organ or region-specific delivery of therapeutic agents. The Company's intellectual property portfolio currently consists of 12 patents on a worldwide basis, including the United States, Europe, Asia and Canada. In May 2005, Delcath received fast-track status from the U.S. FDA for the treatment of metastatic melanoma in the liver with melphalan, an approved anticancer agent, using the Delcath system. For more information, please visit the Company's website, http://www.delcath.com/. This release contains "forward-looking statements" based on current expectations but involving known and unknown risks and uncertainties. Actual results or achievements may be materially different from those expressed or implied. Delcath plans and objectives are based on assumptions involving judgments with respect to future economic, competitive and market conditions, its ability to consummate, and the timing of, acquisitions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond its control. Therefore, there can be no assurance than any forward-looking statement will prove to be accurate. DATASOURCE: Delcath Systems, Inc. CONTACT: Todd Fromer of KCSA Worldwide, +1-212-896-1215, , or Michael Cimini, +1-212-896-1233, Web site: http://www.delcath.com/

Copyright